Table 1.
Patients and tumour characteristics for 199 lung cancer patients scheduled for treatment with erlotinib
| Number | Percent | |
|---|---|---|
|
Gender |
|
|
| Male |
101 |
51 |
| Female |
98 |
49 |
|
Ethnicity |
|
|
| Asian |
1 |
<1 |
| Caucasian |
198 |
>99 |
|
Smoking history |
|
|
| Current smoker |
64 |
32 |
| Former smoker |
118 |
59 |
| Never smoker |
17 |
9 |
|
ECOG performance status* |
|
|
| 0 |
26 |
13 |
| 1 |
99 |
49 |
| 2 |
63 |
32 |
| 3 |
11 |
6 |
|
Tumour type |
|
|
| Adenocarcinoma |
190 |
95 |
| Adenosquamous carcinoma |
9 |
5 |
|
Tumour stage |
|
|
| IIA + IIB |
2 |
1 |
| IIIA + IIIB |
29 |
15 |
| IV |
168 |
84 |
|
Erlotinib therapy |
|
|
| First-line |
22 |
11 |
| Second-line |
156 |
78 |
| Third-line |
16 |
8 |
| Fourth-line |
5 |
3 |
| Age (years, mean (range)) | 64 (33–87) |
*Eastern Cooperative Oncology Group scale to assess how the disease affects the daily living abilities of the patient.